Skip to main content
main-content
Erschienen in: Cardiovascular Toxicology 9/2022

05.08.2022

QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with “Known Risk of Torsades de Pointes”

verfasst von: Kaitlin Ryan, Paul Benz, Amy Zosel, Andrew Farkas, Jillian Theobald

Erschienen in: Cardiovascular Toxicology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Many drugs carry some risk of QT interval prolongation, which can lead to life-threatening dysrhythmias including Torsades de Pointes (TdP). CredibleMeds.org identifies medications categorized as “Known Risk of TdP” but does not stratify risk in acute supratherapeutic ingestions. We sought to determine the proportion of cases exhibiting QTc prolongation and life-threatening dysrhythmias including ventricular tachycardia (VT)/ventricular fibrillation (VF), TdP, and asystole in patients exposed to these substances. Retrospective chart review of cases reported to our Regional Poison Center from 2014 to 2019 of exposures to one or more of the “Known Risk” substances was performed. Demographics, therapies, clinical effects, and medical outcome for each case were analyzed. There were 1125 exposures, of which 760 had a documented QTc interval. QTc ≥ 500 ms was reported in 138 (18.2%) of the 760 cases. The most common “Known Risk” substances were citalopram, escitalopram and cocaine. Although not in the “Known Risk” category, mirtazapine, amitriptyline, diphenhydramine, and trazodone had a statistically significant association with QTc > 500 ms. Life-threatening dysrhythmias occurred in 13 cases, with VT/VF in 6 of the 760 (0.8%) cases, and one case of TdP. Flecainide (OR 11.1, 95% CI 2.2–55.8) and methadone (OR 7.1, 95% CI 2.1–23.4) were associated with increased risk of all life-threatening dysrhythmias. Exposures to medications on the Credible Meds list of “Known Risk of TdP” QTc prolongation is common, but life-threatening dysrhythmias are rare. Mirtazapine, amitriptyline, diphenhydramine, and trazodone were associated with prolonged QTc. Flecainide and methadone had the highest associated risk of life-threatening dysrhythmias.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Yates, C., & Manini, A. F. (2012). Utility of the electrocardiogram in drug overdose and poisoning: Theoretical considerations and clinical implications. Current Cardiology Reviews, 8(2), 137–151. CrossRef Yates, C., & Manini, A. F. (2012). Utility of the electrocardiogram in drug overdose and poisoning: Theoretical considerations and clinical implications. Current Cardiology Reviews, 8(2), 137–151. CrossRef
2.
Zurück zum Zitat Woosley, R. L., Heise, C. W., & Romero, K. A. (2018). QTdrugs list, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755 Retrieved July 6, 2018, from www.​Crediblemeds.​org Woosley, R. L., Heise, C. W., & Romero, K. A. (2018). QTdrugs list, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755 Retrieved July 6, 2018, from www.​Crediblemeds.​org
3.
Zurück zum Zitat Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V., Philippides, G. J., Roden, D. M., Zareba, W., American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology Foundation. (2010). Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation, 121(8), 1047–1060. CrossRef Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V., Philippides, G. J., Roden, D. M., Zareba, W., American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology Foundation. (2010). Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation, 121(8), 1047–1060. CrossRef
4.
Zurück zum Zitat Tisdale, J. E., Jaynes, H. A., Kingery, J. R., Overholser, B. R., Mourad, N. A., Trujillo, T. N., & Kovacs, R. J. (2014). Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circulation Cardiovascular Quality and Outcomes, 7(3), 381–390. CrossRef Tisdale, J. E., Jaynes, H. A., Kingery, J. R., Overholser, B. R., Mourad, N. A., Trujillo, T. N., & Kovacs, R. J. (2014). Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circulation Cardiovascular Quality and Outcomes, 7(3), 381–390. CrossRef
5.
Zurück zum Zitat Isbister, G. K. (2015). Risk assessment of drug-induced QT prolongation. Australian Prescriber, 38(1), 20–24. CrossRef Isbister, G. K. (2015). Risk assessment of drug-induced QT prolongation. Australian Prescriber, 38(1), 20–24. CrossRef
6.
Zurück zum Zitat Pourmand, A., Mazer-Amirshahi, M., Chistov, S., Sabha, Y., Vukomanovic, D., & Almulhim, M. (2017). Emergency department approach to QTc prolongation. American Journal of Emergency Medicine, 35(12), 1928–1933. CrossRef Pourmand, A., Mazer-Amirshahi, M., Chistov, S., Sabha, Y., Vukomanovic, D., & Almulhim, M. (2017). Emergency department approach to QTc prolongation. American Journal of Emergency Medicine, 35(12), 1928–1933. CrossRef
7.
Zurück zum Zitat Heemskerk, C. P. M., Pereboom, M., van Stralen, K., Berger, F. A., van den Bemt, P. M. L. A., Kuijper, A. F. M., van der Hoeven, R. T. M., Mantel-Teeuwisse, A. K., & Becker, M. L. (2018). Risk factors for QTc interval prolongation. European Journal of Clinical Pharmacology, 74(2), 183–191. CrossRef Heemskerk, C. P. M., Pereboom, M., van Stralen, K., Berger, F. A., van den Bemt, P. M. L. A., Kuijper, A. F. M., van der Hoeven, R. T. M., Mantel-Teeuwisse, A. K., & Becker, M. L. (2018). Risk factors for QTc interval prolongation. European Journal of Clinical Pharmacology, 74(2), 183–191. CrossRef
8.
Zurück zum Zitat Berling, I., & Isbister, G. K. (2015). Prolonged QT Risk assessment in antipsychotic overdose using the QT nomogram. Annals of Emergency Medicine, 66(2), 154–164. CrossRef Berling, I., & Isbister, G. K. (2015). Prolonged QT Risk assessment in antipsychotic overdose using the QT nomogram. Annals of Emergency Medicine, 66(2), 154–164. CrossRef
9.
Zurück zum Zitat Baker, W. L. (2017). Treating arrhythmias with adjunctive magnesium: Identifying future research directions. European Heart Journal Cardiovascular Pharmacother, 3(2), 108–117. Baker, W. L. (2017). Treating arrhythmias with adjunctive magnesium: Identifying future research directions. European Heart Journal Cardiovascular Pharmacother, 3(2), 108–117.
10.
Zurück zum Zitat Schwartz, P. J., & Woosley, R. L. (2016). Predicting the unpredictable: Drug-induced QT prolongation and torsades de pointes. Journal of the American College of Cardiology, 67(13), 1639–1650. CrossRef Schwartz, P. J., & Woosley, R. L. (2016). Predicting the unpredictable: Drug-induced QT prolongation and torsades de pointes. Journal of the American College of Cardiology, 67(13), 1639–1650. CrossRef
11.
Zurück zum Zitat Pérez-Riera, A. R., Barbosa-Barros, R., Raimundo, R. D., de Rezende, M. P. D. C., Sorpreso, I. C. E., & de Abreu, L. C. (2018). The congenital long QT syndrome Type 3: An update. Indian Pacing Electrophysiology Journal, 18(1), 25–35. CrossRef Pérez-Riera, A. R., Barbosa-Barros, R., Raimundo, R. D., de Rezende, M. P. D. C., Sorpreso, I. C. E., & de Abreu, L. C. (2018). The congenital long QT syndrome Type 3: An update. Indian Pacing Electrophysiology Journal, 18(1), 25–35. CrossRef
12.
Zurück zum Zitat von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2014). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. International Journal of Surgery, 12(12), 1495–1499. CrossRef von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2014). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. International Journal of Surgery, 12(12), 1495–1499. CrossRef
14.
Zurück zum Zitat van Gorp, F., Whyte, I. M., & Isbister, G. K. (2009). Clinical and ECG effects of escitalopram overdose. Annals of Emergency Medicine, 54(3), 404–408. CrossRef van Gorp, F., Whyte, I. M., & Isbister, G. K. (2009). Clinical and ECG effects of escitalopram overdose. Annals of Emergency Medicine, 54(3), 404–408. CrossRef
15.
Zurück zum Zitat Berling, I., & Isbister, G. K. (2014). Mirtazapine overdose is unlikely to cause major toxicity. Clinical Toxicology (Philadelphia, PA), 52(1), 20–24. CrossRef Berling, I., & Isbister, G. K. (2014). Mirtazapine overdose is unlikely to cause major toxicity. Clinical Toxicology (Philadelphia, PA), 52(1), 20–24. CrossRef
16.
Zurück zum Zitat Manini, A. F., Nair, A. P., Vedanthan, R., Vlahov, D., & Hoffman, R. S. (2017). Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose. Journal of the American Heart Association, 6(2), e004320. CrossRef Manini, A. F., Nair, A. P., Vedanthan, R., Vlahov, D., & Hoffman, R. S. (2017). Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose. Journal of the American Heart Association, 6(2), e004320. CrossRef
17.
Zurück zum Zitat Othong, R., Devlin, J. J., & Kazzi, Z. N. (2015). Medical toxicologists’ practice patterns regarding drug-induced QT prolongation in overdose patients: A survey in the United States of America, Europe, and Asia Pacific region. Clinical Toxicology (Philadelphia, PA), 53(4), 204–209. CrossRef Othong, R., Devlin, J. J., & Kazzi, Z. N. (2015). Medical toxicologists’ practice patterns regarding drug-induced QT prolongation in overdose patients: A survey in the United States of America, Europe, and Asia Pacific region. Clinical Toxicology (Philadelphia, PA), 53(4), 204–209. CrossRef
18.
Zurück zum Zitat Manini, A. F., Nelson, L. S., Skolnick, A. H., Slater, W., & Hoffman, R. S. (2010). Electrocardiographic predictors of adverse cardiovascular events in suspected poisoning. Journal of Medical Toxicology, 6(2), 106–115. CrossRef Manini, A. F., Nelson, L. S., Skolnick, A. H., Slater, W., & Hoffman, R. S. (2010). Electrocardiographic predictors of adverse cardiovascular events in suspected poisoning. Journal of Medical Toxicology, 6(2), 106–115. CrossRef
19.
Zurück zum Zitat Jang, D. H., Spyres, M. B., Fox, L., & Manini, A. F. (2014). Toxin-induced cardiovascular failure. Emergency Medicine Clinics of North America, 32(1), 79–102. CrossRef Jang, D. H., Spyres, M. B., Fox, L., & Manini, A. F. (2014). Toxin-induced cardiovascular failure. Emergency Medicine Clinics of North America, 32(1), 79–102. CrossRef
20.
Zurück zum Zitat Berling, I., Hatten, B. W., Hoffman, R. S., Othong, R., Roberts, D. M., Mustafa, R. A., Yates, C., Cormier, M., & Gosselin, S. (2020). Guidelines for reporting case studies and series on drug-induced QT interval prolongation and its complications following acute overdose. Clinical Toxicology (Philadelphia, PA), 58(1), 20–28. https://​doi.​org/​10.​1080/​15563650.​2019.​1605077 Epub 2019 Apr 24. CrossRef Berling, I., Hatten, B. W., Hoffman, R. S., Othong, R., Roberts, D. M., Mustafa, R. A., Yates, C., Cormier, M., & Gosselin, S. (2020). Guidelines for reporting case studies and series on drug-induced QT interval prolongation and its complications following acute overdose. Clinical Toxicology (Philadelphia, PA), 58(1), 20–28. https://​doi.​org/​10.​1080/​15563650.​2019.​1605077 Epub 2019 Apr 24. CrossRef
Metadaten
Titel
QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with “Known Risk of Torsades de Pointes”
verfasst von
Kaitlin Ryan
Paul Benz
Amy Zosel
Andrew Farkas
Jillian Theobald
Publikationsdatum
05.08.2022
Verlag
Springer US
Erschienen in
Cardiovascular Toxicology / Ausgabe 9/2022
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-022-09764-4

Weitere Artikel der Ausgabe 9/2022

Cardiovascular Toxicology 9/2022 Zur Ausgabe